<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05072015</url>
  </required_header>
  <id_info>
    <org_study_id>8355</org_study_id>
    <nct_id>NCT05072015</nct_id>
  </id_info>
  <brief_title>Systematic Follow up of Second Line Treatments for Parkinson's Disease (Deep Brain Stimulation, Apomorphin Pump, Duodopa Pump)</brief_title>
  <acronym>TeSLa-PD</acronym>
  <official_title>Systematic Follow up of Second Line Treatments for Parkinson's Disease (Deep Brain Stimulation, Apomorphin Pump, Duodopa Pump)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary purpose: Fluctuations and dyskinesia evolution in Parkinson's disease patients, one&#xD;
      year after initiation of deep brain stimulation, apomorphin pump or duodopa pump&#xD;
&#xD;
      Secundary purposes:&#xD;
&#xD;
        -  Motor complications evolution at 6 months, 2 and 3 years&#xD;
&#xD;
        -  MDS UPDRS III score at 6 months, 1, 2 and 3 years&#xD;
&#xD;
        -  non motor complications evolution at 6 months, 1, 2 and 3 years&#xD;
&#xD;
        -  cognition and psychiatric complications evolution at 6 months, 1, 2 and 3 years&#xD;
&#xD;
        -  cutaneous and digestive complications at 6 months, 1, 2 and 3 years&#xD;
&#xD;
        -  neuropathy occurrence at 6 months, 1, 2 and 3 years&#xD;
&#xD;
        -  medical treatment and Levodopa equivalent dose modifications at 6 months, 1, 2 and 3&#xD;
           years&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">September 2027</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>MDS UPDRS IV score improvement</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluate the evolution of motor fluctuations and dyskinesias at one year in patients treated with one of the 3 TSLs (bilateral stimulation of the subthalamic nucleus, apomorphine pump and duodopa pump</description>
  </primary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Parkinson's Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with advanced Parkinson' s disease who need second line treatment&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Parkinson disease (UKPDSSB criteria)&#xD;
&#xD;
          -  Patient with fluctuations and/or dyskinesia , who need treatment with deep brain&#xD;
             stimulation, apomorphin pump or duodopa pump&#xD;
&#xD;
          -  MOCA &gt;20&#xD;
&#xD;
          -  patient &gt;21 years of age&#xD;
&#xD;
          -  patient who has signed protocol acceptation&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  patient who did not give his acceptation for the protocol&#xD;
&#xD;
          -  patient with another parkinsonian syndrome than Parkinson' s disease&#xD;
&#xD;
          -  MOCA&lt;20&#xD;
&#xD;
          -  Patient who does not need second line treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mathieu ANHEIM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Les HÃ´pitaux Universitaires de Strasbourg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mathieu ANHEIM</last_name>
    <phone>+33 3 88 12 85 35</phone>
    <email>mathieu.anheim@chru-strasbourg.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mathieu ANHEIM</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Mathieu ANHEIM</last_name>
      <phone>+33388128535</phone>
      <email>mathieu.anheim@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Mathieu ANHEIM</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christine TRANCHANT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ouhaid LAGHA BOUKBIZA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas WIRTH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 30, 2021</study_first_submitted>
  <study_first_submitted_qc>September 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2021</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

